BriaCell Therapeutics Announces Closing of $15 million Public Offering

Core Viewpoint - BriaCell Therapeutics Corp. has successfully closed a public offering of 12 million units, raising gross proceeds of $15 million to support its cancer immunotherapy development [1][3]. Group 1: Offering Details - The offering consisted of 12,000,000 units, each unit priced at $1.25, which includes one common share or one pre-funded warrant and one warrant [1]. - Each pre-funded warrant allows the purchase of one common share at an exercise price of $0.001, while each warrant is exercisable at $1.50 per share for five years [1]. - The offering was conducted without a Canadian prospectus, relying on an exemption under the TSX Company Manual [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and advancing business objectives [3]. Group 3: Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering made only by means of a prospectus [4].